Video

Dr. Leyland-Jones Discusses the Phase III HERA Trial

Brian Leyland-Jones, MBBS, PhD, discusses results from the phase III HERA trial that compared 2 years of adjuvant trastuzumab to the standard 1 year in HER2-postive early-stage breast cancer.

Brian Leyland-Jones, MBBS, PhD, director of Edith Sanford Breast Cancer Research, discusses results from an 8 year follow-up of the phase III HERA trial that compared 2 years of adjuvant trastuzumab to the standard 1 year in 5102 women with HER2-postive early-stage breast cancer.

Leyland-Jones believes that the length of time needed to reach the expected 725 events needed to power a survival analysis provides great news for patients with breast cancer. Many believed these results would be available sooner than 8 years. In general, the results for the two arms of the trial were similar, showing no additional benefit for 2 years of trastuzumab. Prior to this trial, Leyland-Jones believed an added benefit would be observed.

The adjusted hazard ratio (HR) for disease free survival for two years versus one of adjuvant trastuzumab was 0.99. The HR for overall survival between the two arms was 1.05. The overlapping of these curves demonstrates no benefit for an additional year of trastuzumab, Leyland-Jones explains.

<<<

View coverage from the 2012 SABCS

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
Adam M. Brufsky, MD, PhD, FACP
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Chirag Shah, MD
Jason A. Mouabbi, MD
2 KOLs are featured in this program.